Lasne Dominique, Pascreau Tiffany, Darame Sadyo, Bourrienne Marie-Charlotte, Tournoux Peggy, Philippe Aurélien, Ziachahabi Sara, Suarez Felipe, Marcais Ambroise, Dupont Annabelle, Denis Cécile V, Kauskot Alexandre, Borgel Delphine
Department of Biological Hematology Hôpital Necker AP-HP Paris France.
HITh UMR_S 1176 INSERM Univ. Paris-Saclay Le Kremlin-Bicêtre France.
Res Pract Thromb Haemost. 2020 Jun 2;4(5):813-822. doi: 10.1002/rth2.12369. eCollection 2020 Jul.
Correct diagnosis of the cause of thrombocytopenia is crucial for the appropriate management of patients. Hyposialylation/desialylation (characterized by abnormally high β-galactose exposure) accelerates platelet clearance and can lead to thrombocytopenia. However, the reference range for β-galactose exposure in healthy individuals has not been defined previously.
The objective of the present study was to develop a standardized assay of platelet β-galactose exposure for implementation in a clinical laboratory.
β-Galactose exposure was measured in platelet-rich plasma by using flow cytometry and agglutinin (RCA). A population of 120 healthy adults was recruited to study variability.
We determined an optimal RCA concentration of 12.5 μg/mL. The measure was stable for up to 4 hours (mean fluorescence intensity [MFI]-RCA: 1233 ± 329 at 0 hour and 1480 ± 410 at 4 hours). The platelet count did not induce a variation of RCA and the measure of RCA was stable when tested up to 24 hours after blood collection (MFI-RCA: 1252 ± 434 at day 0 and 1140 ± 297 24 hours after blood sampling). To take into account the platelet size, results should be expressed as RCA/forward scatter ratio. We used the assay to study variability in 120 healthy adults, and we found that the ratio is independent of sex and blood group.
We defined a normal range in a healthy population and several preanalytical and analytical variables were evaluated, together with positive and negative controls. This assay may assist in the diagnosis of thrombocytopenic diseases linked to changes in β-galactose exposure.
正确诊断血小板减少的病因对于患者的恰当管理至关重要。低唾液酸化/去唾液酸化(特征为异常高的β-半乳糖暴露)会加速血小板清除并可导致血小板减少。然而,此前尚未确定健康个体中β-半乳糖暴露的参考范围。
本研究的目的是开发一种标准化的血小板β-半乳糖暴露检测方法,以便在临床实验室中应用。
通过流式细胞术和凝集素(RCA)测量富血小板血浆中的β-半乳糖暴露。招募了120名健康成年人以研究变异性。
我们确定了12.5μg/mL的最佳RCA浓度。该测量在长达4小时内稳定(平均荧光强度[MFI]-RCA:0小时时为1233±329,4小时时为1480±410)。血小板计数未引起RCA的变化,且在采血后长达24小时进行检测时,RCA测量稳定(MFI-RCA:第0天为1252±434,采血24小时后为1140±297)。为考虑血小板大小,结果应以RCA/前向散射比值表示。我们使用该检测方法研究了120名健康成年人的变异性,发现该比值与性别和血型无关。
我们定义了健康人群的正常范围,并评估了几个分析前和分析变量以及阳性和阴性对照。该检测方法可能有助于诊断与β-半乳糖暴露变化相关的血小板减少性疾病。